Cystatin C in cerebrospinal fluid and multiple sclerosis
暂无分享,去创建一个
Anders Wallin | Henrik Zetterberg | Kaj Blennow | Ann Westman-Brinkmalm | K. Blennow | H. Zetterberg | A. Wallin | U. Andréasson | A. Simonsen | A. Westman-Brinkmalm | O. Andersen | S. Hansson | Sara F Hansson | Ulf Andréasson | Anja Hviid Simonsen | Oluf Andersen | Sara Haghighi | Inger Fagerberg | Ulla Rüetschi | S. Haghighi | U. Rüetschi | Inger Fagerberg | U. Andreasson | A. Westman‐Brinkmalm
[1] C. Poser. CLINICAL DIAGNOSTIC CRITERIA IN EPIDEMIOLOGICAL STUDIES OF MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.
[2] Justin C McArthur,et al. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis , 2006, Annals of neurology.
[3] J. Barrett,et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. , 2005, Clinical chemistry.
[4] Jean-Charles Sanchez,et al. Truncated cystatin C in cerebrospiral fluid: Technical artefact or biological process? , 2005 .
[5] Jean-Charles Sanchez,et al. Truncated cystatin C in cerebrospiral fluid: Technical [corrected] artefact or biological process? , 2005, Proteomics.
[6] Jeffrey S. Morris,et al. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..
[7] L. Rosengren,et al. Incidence of CSF abnormalities in siblings of multiple sclerosis patients and unrelated controls , 2000, Journal of Neurology.
[8] Jean-Charles Sanchez,et al. Proteomics: new perspectives, new biomedical opportunities , 2000, The Lancet.
[9] E. Marchiori,et al. Sample handling for mass spectrometric proteomic investigations of human sera. , 2005, Analytical chemistry.